FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200190248> ?p ?o ?g. }

• W4200190248 endingPage "506" @default.
• W4200190248 startingPage "494" @default.
• W4200190248 abstract "Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. In the 6-month double-blind period (DBP) of ILLUMINATE-A, a phase 3, randomized, placebo-controlled trial in patients with PH1 ≥6 years old, treatment with lumasiran, an RNA interference therapeutic, led to substantial reductions in urinary oxalate (UOx) levels.We report data to month 12 in the extension period (EP) of ILLUMINATE-A, including patients who continued lumasiran (lumasiran/lumasiran) or crossed over from placebo to lumasiran (placebo/lumasiran).In the lumasiran/lumasiran group (n = 24), the reduction in 24-hour UOx level was sustained to month 12 (mean reduction from baseline, 66.9% at month 6; 64.1% at month 12). The placebo/lumasiran group (n = 13) had a similar time course and magnitude of 24-hour UOx reduction (mean reduction, 57.3%) after 6 months of lumasiran. Kidney stone event rates seemed to be lower after 6 months of lumasiran in both groups compared with the 12 months before consent, and this reduction was maintained at month 12 in the lumasiran/lumasiran group. At study start, 71% of patients in the lumasiran/lumasiran group and 92% in the placebo/lumasiran group had nephrocalcinosis. Nephrocalcinosis grade improved after 6 months of lumasiran in the lumasiran/lumasiran and placebo/lumasiran groups (13% and 8% of patients, respectively). After an additional 6 months of lumasiran, 46% of patients had improvement in nephrocalcinosis grade within the lumasiran/lumasiran group. Estimated glomerular filtration rate (eGFR) remained stable during the course of lumasiran treatment. The most common adverse events (AEs) related to lumasiran were mild, transient injection-site reactions (ISRs).Long-term lumasiran treatment enabled sustained lowering of UOx levels with acceptable safety and encouraging results on clinical outcomes." @default.
• W4200190248 created "2021-12-31" @default.
• W4200190248 creator A5004837566 @default.
• W4200190248 creator A5007565150 @default.
• W4200190248 creator A5015100871 @default.
• W4200190248 creator A5017408040 @default.
• W4200190248 creator A5027867729 @default.
• W4200190248 creator A5028046519 @default.
• W4200190248 creator A5032891959 @default.
• W4200190248 creator A5039956174 @default.
• W4200190248 creator A5042385774 @default.
• W4200190248 creator A5047361703 @default.
• W4200190248 creator A5048525391 @default.
• W4200190248 creator A5052121446 @default.
• W4200190248 creator A5061479404 @default.
• W4200190248 creator A5070466849 @default.
• W4200190248 creator A5070639365 @default.
• W4200190248 creator A5073738348 @default.
• W4200190248 creator A5078342350 @default.
• W4200190248 creator A5080532594 @default.
• W4200190248 creator A5083531787 @default.
• W4200190248 creator A5086099648 @default.
• W4200190248 creator A5087268876 @default.
• W4200190248 creator A5090129123 @default.
• W4200190248 date "2022-03-01" @default.
• W4200190248 modified "2023-10-14" @default.
• W4200190248 title "Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1" @default.
• W4200190248 cites W1963912010 @default.
• W4200190248 cites W1967634723 @default.
• W4200190248 cites W1998318998 @default.
• W4200190248 cites W2024896415 @default.
• W4200190248 cites W2047836558 @default.
• W4200190248 cites W2075121105 @default.
• W4200190248 cites W2081241147 @default.
• W4200190248 cites W2106951882 @default.
• W4200190248 cites W2109537432 @default.
• W4200190248 cites W2109644074 @default.
• W4200190248 cites W2136057046 @default.
• W4200190248 cites W2139069224 @default.
• W4200190248 cites W2161471021 @default.
• W4200190248 cites W2496344419 @default.
• W4200190248 cites W2740296225 @default.
• W4200190248 cites W3012340007 @default.
• W4200190248 cites W3012630306 @default.
• W4200190248 cites W3151149834 @default.
• W4200190248 cites W3162171920 @default.
• W4200190248 cites W4236938577 @default.
• W4200190248 doi "https://doi.org/10.1016/j.ekir.2021.12.001" @default.
• W4200190248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35257062" @default.
• W4200190248 hasPublicationYear "2022" @default.
• W4200190248 type Work @default.
• W4200190248 citedByCount "9" @default.
• W4200190248 countsByYear W42001902482022 @default.
• W4200190248 countsByYear W42001902482023 @default.
• W4200190248 crossrefType "journal-article" @default.
• W4200190248 hasAuthorship W4200190248A5004837566 @default.
• W4200190248 hasAuthorship W4200190248A5007565150 @default.
• W4200190248 hasAuthorship W4200190248A5015100871 @default.
• W4200190248 hasAuthorship W4200190248A5017408040 @default.
• W4200190248 hasAuthorship W4200190248A5027867729 @default.
• W4200190248 hasAuthorship W4200190248A5028046519 @default.
• W4200190248 hasAuthorship W4200190248A5032891959 @default.
• W4200190248 hasAuthorship W4200190248A5039956174 @default.
• W4200190248 hasAuthorship W4200190248A5042385774 @default.
• W4200190248 hasAuthorship W4200190248A5047361703 @default.
• W4200190248 hasAuthorship W4200190248A5048525391 @default.
• W4200190248 hasAuthorship W4200190248A5052121446 @default.
• W4200190248 hasAuthorship W4200190248A5061479404 @default.
• W4200190248 hasAuthorship W4200190248A5070466849 @default.
• W4200190248 hasAuthorship W4200190248A5070639365 @default.
• W4200190248 hasAuthorship W4200190248A5073738348 @default.
• W4200190248 hasAuthorship W4200190248A5078342350 @default.
• W4200190248 hasAuthorship W4200190248A5080532594 @default.
• W4200190248 hasAuthorship W4200190248A5083531787 @default.
• W4200190248 hasAuthorship W4200190248A5086099648 @default.
• W4200190248 hasAuthorship W4200190248A5087268876 @default.
• W4200190248 hasAuthorship W4200190248A5090129123 @default.
• W4200190248 hasBestOaLocation W42001902481 @default.
• W4200190248 hasConcept C126322002 @default.
• W4200190248 hasConcept C126894567 @default.
• W4200190248 hasConcept C141071460 @default.
• W4200190248 hasConcept C142724271 @default.
• W4200190248 hasConcept C168563851 @default.
• W4200190248 hasConcept C202061045 @default.
• W4200190248 hasConcept C204787440 @default.
• W4200190248 hasConcept C27081682 @default.
• W4200190248 hasConcept C2778653478 @default.
• W4200190248 hasConcept C2779403450 @default.
• W4200190248 hasConcept C2780091579 @default.
• W4200190248 hasConcept C2781092957 @default.
• W4200190248 hasConcept C2781145721 @default.
• W4200190248 hasConcept C2991744798 @default.
• W4200190248 hasConcept C71924100 @default.
• W4200190248 hasConcept C90924648 @default.
• W4200190248 hasConceptScore W4200190248C126322002 @default.
• W4200190248 hasConceptScore W4200190248C126894567 @default.
• W4200190248 hasConceptScore W4200190248C141071460 @default.
• W4200190248 hasConceptScore W4200190248C142724271 @default.

• next